Bildkälla: Stockfoto

Sprint Bioscience Q1 2022: NIMA launch in June - Redeye

Redeye comments on Sprint’s Q1 2022 report, with the company recently announcing the target and launch date for its internal NIMA project. We are encouraged by the company’s project portfolio progressing on all fronts and revise our assumptions for VADA.

Redeye comments on Sprint’s Q1 2022 report, with the company recently announcing the target and launch date for its internal NIMA project. We are encouraged by the company’s project portfolio progressing on all fronts and revise our assumptions for VADA.
Börsvärldens nyhetsbrev
ANNONSER